NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
American Society of Clinical Oncology (ASCO) 2018 – Poster
A PHASE 1 OPEN-LABEL, SAFETY, PHARMACOKINETIC, AND PRELIMINARY EFFICACY STUDY OF STRO-001, AN ANTI-CD74 ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES, NCT03424603
Sutro CEO, Bill Newell appointed Chair of the California Life Sciences Association.
https://califesciences.org/california-life-sciences-association-elects-new-board-chair-adds-new-board-member/ California Life Sciences Association Elects New Board Chair, Vice Chair And Adds New Board Member SAN FRANCISCO, SACRAMENTO & SAN DIEGO, Calif., May 30,...
Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs
SOUTH SAN FRANCISCO, April 26, 2018 -- Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its potential first-in-class antibody drug conjugate, or ADC, product candidate, STRO-001, targeting CD74, a protein highly expressed in B-cell...
American Association for Cancer Research (AACR) 2018 – STRO-002 Poster
Discovery and Activity of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian and Endometrial Cancer STRO-002 AACR 2018 Poster Final
Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research
- Phase 1 Trial Planned for Late 2018 - Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate (ADC) to treat solid tumors was highly effective against ovarian cancer in...
American Association for Cancer Research (AACR) 2018 – STRO-002 Abstract
Generation and Activity of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Folate receptor alpha (FolRa) is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is highly expressed in serous and epithelial ovarian cancer...
Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Abstract
Preclinical Activity and Safety of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Objectives: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed in ovarian and endometrial adenocarcinoma, that is a promising target...
Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Poster
STRO-001 – Publication Highlights
Pan Pacific Lymphoma, 2018 HIGH FREQUENCY OF CD74 EXPRESSION IN B-CELL NON-HODGKIN’S LYMPHOMA (NHL) AND TARGETING WITH STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) WITH POTENT IN VITROCYTOTOXICTY AND IN VIVOANTI-TUMOR ACTIVITY A Yu1, C Abrahams1, M...
Science and Platform Publication Highlights
Biotechnol Bioeng. 2011 Jul;108(7):1570-8. doi: 10.1002/bit.23103. Epub 2011 Mar 31. Microscale to manufacturing scale-up of cell-free cytokine production--a new approach for shortening protein production development timelines. Zawada JF, Yin G, Steiner AR, Yang J,...